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Alzheimer’s disease is the most common age-related neurodegenerative disorder. Familial forms of Alzheimer’s disease
associated with the accumulation of a toxic form of amyloid-β (Aβ) peptides are linked to mitochondrial impairment. The
coenzyme nicotinamide adenine dinucleotide (NAD+) is essential for both mitochondrial bioenergetics and nuclear DNA repair
through NAD+-consuming poly (ADP-ribose) polymerases (PARPs). Here we analysed the metabolomic changes in flies
overexpressing Aβ and showed a decrease of metabolites associated with nicotinate and nicotinamide metabolism, which is
critical for mitochondrial function in neurons. We show that increasing the bioavailability of NAD+ protects against Aβ toxicity.
Pharmacological supplementation using NAM, a form of vitamin B that acts as a precursor for NAD+ or a genetic mutation of
PARP rescues mitochondrial defects, protects neurons against degeneration and reduces behavioural impairments in a fly
model of Alzheimer’s disease. Next, we looked at links between PARP polymorphisms and vitamin B intake in patients with
Alzheimer’s disease. We show that polymorphisms in the human PARP1 gene or the intake of vitamin B are associated with a
decrease in the risk and severity of Alzheimer’s disease. We suggest that enhancing the availability of NAD+ by either
vitamin B supplements or the inhibition of NAD+-dependent enzymes such as PARPs are potential therapies for Alzheimer’s
disease.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia
and a major risk factor for developing other diseases [1–4]. There
is no cure for AD. Hence, preventive strategies are urgently
needed. Familial AD is associated with the accumulation of a
toxic form of the amyloid-β (Aβ) peptide in the brain [5–8].
Animal models of AD in the fruit fly Drosophila melanogaster
were generated by expressing toxic human Aβ in the fly’s
neurons [9]. The neuronal expression of the disease-associated
Aβ (1-42), with an Arctic mutation (Glu22Gly) (Aβ-Arc), resulted
in its accumulation in the neuronal cells. The accumulation of
Aβ-Arc in turn causes neurodegeneration and premature
neuronal cell death, recapitulating pathological features of AD
in humans (reviewed in [10]). Flies are therefore a powerful
animal model for studying the mechanisms of neurodegenera-
tion and the identification of novel preventive strategies for this
disease [11].
Mitochondria are the cell’s powerhouses. They produce
adenosine triphosphate (ATP) as the cellular energy currency.
Their compromise has serious consequences for animal tissues
with high energetic demands, such as the brain and muscle. The
prevailing consensus is that, in AD, mitochondrial impairment is an
epiphenomenon of a dysfunctional neuron, secondary to toxic
molecular-initiating events (reviewed in [12]).
Nicotinamide adenine dinucleotide (NAD+) is important for the
generation of ATP and the maintenance of redox balance in the
mitochondria. In addition, NAD+ is also essential for DNA repair
mechanisms in the cell nucleus involving the NAD+-consuming
enzyme, poly (ADP-ribose) polymerase (PARP). The levels of NAD+
are governed by the rates of biosynthesis, consumption, recycling
or degradation of this metabolite (reviewed in [13]). In models of
mitochondrial dysfunction, increasing the bioavailability of NAD+
improves mitochondrial function, enhances oxidative metabolism
and general fitness [13]. The inhibition of major NAD+-consuming
enzymes, such as PARP, or the dietary supplementation of its
precursor increases NAD+ levels, protects against mitochondrial
dysfunction and improves lifespan in fly models of neurodegen-
eration linked to Parkinson’s disease [14, 15].
Here we explore the metabolic consequences of the expres-
sion of toxic Aβ-Arc in flies. We find that metabolites involved in
nicotinamide (NAM) metabolism, in particular NAD+, are altered.
We show that the dietary supplementation of an NAD+ precursor
vitamin, NAM (or vitamin B3), and the genetic suppression of the
NAD+ consuming enzyme, Parp, improves mitochondrial func-
tion and prevents neurodegeneration in flies expressing Aβ-Arc
in neurons. We then sought to validate the relationship between
NAM, PARP and AD in humans using data from the UK Biobank.
We identified three variants in the PARP1 gene associated with
AD and show that participants taking vitamin B, which contains
NAM, have lower risk and severity of AD. Our results highlight an
important role of mitochondria in AD and the potential for
NAD+-based therapies.
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RESULTS
Identification of a metabolic signature linked to nicotinate
and NAM metabolism in flies expressing toxic Aβ
To study the metabolic alterations caused by the expression of
toxic Aβ in an in vivo model, we conducted a global analysis of the
metabolome of adult flies expressing a secreted form of Aβ-Arc [9]
in neurons. We found that approximately 30% of the biochemicals
measured in whole flies are significantly altered by neuronal
expression of Aβ-Arc (Fig. 1A and Supplementary Table 1).
Next, we performed a pathway analysis of the biochemicals that
were altered in Aβ-Arc flies. We found that Aβ-Arc causes significant
alterations in the nicotinate and NAM metabolism pathway, an
upregulation in several precursors of the coenzyme NAD+ belonging
to the tryptophan metabolism pathway and a decrease in NAD+,
which is essential for generating energy in mitochondria (Fig. 1B, C).
Mitochondrial dysfunction is often described in models of AD but
the current view is that it represents a secondary feature of a
damaged neuron (reviewed in [12]). We therefore tested whether
the decrease in NAD+ levels observed in adult flies expressing
Aβ-Arc was associated with mitochondrial dysfunction in the brain.
An ultrastructural analysis by transmission electron microscopy (TEM)
of mitochondria in the adult flies’ brain expressing this toxic form of
Aβ showed defects in mitochondrial morphology (Fig. 2A, B). Aβ-Arc
expressing flies showed a loss of mitochondrial membrane potential
(Δψm), indicating a compromise in mitochondrial function (Fig. 2C,
D). These findings demonstrate that the mitochondrial impairment
caused by neuronal expression of toxic Aβ in flies is linked to
decreased NAD+ metabolism.
A NAM-supplemented diet suppresses mitochondrial
dysfunction and neurodegeneration in flies expressing toxic
Aβ
The co-enzyme NAD+ is an essential component of the mitochon-
drial electron transport chain. NAD+ is made from NAM, the amide
form of nicotinic acid, also known as niacin or vitamin B3 (Fig. 1C).
Hence, we tested the effects of enhancing NAD+ in flies expressing
toxic Aβ with a diet supplemented with NAM.
Flies expressing Aβ-Arc exposed to a NAM-supplemented diet
showed an increase in their NAD+ pools (Fig. 3A). The dietary
supplementation with NAM enhanced Δψm in neuronal mitochon-
dria of flies expressing Aβ-Arc (Fig. 3B), indicating that a NAM-
supplemented diet improves mitochondrial function. Expression of
toxic Aβ causes age-dependent neurodegeneration in retinal
photoreceptor cells. We next tested the effect of a NAM-
supplemented diet on the degeneration of retinal photoreceptors
of Aβ-Arc-expressing flies. We showed that flies kept on a NAM-
supplemented data showed a significant decrease in photoreceptor
neurodegeneration (Fig. 3C–E). We conclude that a dietary supple-
mentation with this formulation of vitamin B3 improves mitochon-
drial function and neuronal health in flies expressing toxic Aβ.
A Parp mutation improves mitochondrial function and
restores neuronal health in Aβ-Arc-expressing flies
The coenzyme NAD+ is not only essential for energy
metabolism but also acts as a co-substrate in biochemical
reactions such as protein ADP-ribosylation (PAR), catalysed by
PARPs, reviewed in [16]. We have previously shown that
mitochondrial dysfunction in pink1 or parkin mutant flies, two
genes implicated in Parkinson’s disease, causes an increase in
PAR levels. Introducing a Parp mutation in either pink1 or parkin
mutants boosted NAD+ levels and protected dopaminergic
neurons loss. As we also detected a loss of mitochondrial
function (Fig. 2C, D) in Aβ-Arc-expressing flies, we compared
the PAR levels between control and Aβ-Arc-expressing flies. We
found that the expression of Aβ-Arc led to an increase in PAR in
whole flies (Fig. 4A). Next, we introduced a Parp mutation in
flies expressing toxic Aβ to test attempt to boost NAD+ levels.
Neuronal expression of toxic Aβ in flies with a Parp mutation
(ParpCH1/+) resulted in an increase in NAD+ levels (Fig. 4B) and
improved mitochondrial function (Fig. 4C).
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Fig. 1 Expression of a toxic form of Aβ results in alterations in tryptophan and nucleotide metabolism. A Workflow employed for the
identification of metabolic changes in adult flies expressing toxic Aβ-Arc. Significance was determined using Welch’s two-sample t test (n indicated
for each sample set). B Pathway enrichment analysis of all significantly altered metabolites. C Expression of Aβ-Arc causes changes in tryptophan
and NADmetabolism. Red and blue correspond to metabolites that are, respectively, significantly upregulated or downregulated. ND corresponds
to a metabolite below detection threshold. Genotypes: control, daGal4>+; Aβ-Arc, daGal4>Aβ-Arc. See also Supplementary Table 1.
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In flies, Aβ toxicity influences neuronal activity and disrupts
sleep [17]. We observed that, in the presence of the Parpmutation,
flies expressing toxic Aβ showed an improvement of their sleep
patterns (Fig. 4D). Moreover, Parp mutation also reduced
neurodegeneration (Fig. 4E) and improved the mid-life survival
of Aβ-Arc-expressing flies (Fig. 4F). We conclude that a mutation in
the Parp gene in flies expressing toxic Aβ rescues mitochondrial
dysfunction and is neuroprotective.
Genetic variants in human PARP1 predict the risk of AD
We found that a mutation in the Drosophila Parp gene protects
flies from Aβ toxicity. This led us to test the association between
genetic variants in the human PARP1 gene and the risk of AD.
The UK Biobank is a biomedical database and research resource
containing health records of more than half a million UK
individuals [18]. Out of a total of 502,505 UK Biobank participants,
we first identified a subset (432,747) with genomic information
(polymorphisms, Supplementary Figs. 1–4 and Supplementary
Tables 2 and 3). From this subset, 847 have a positive diagnosis of
AD (Fig. 5A, B). Next, we screened for the presence of single-
nucleotide polymorphisms (SNPs) in PARP1 and identified 15 SNPs
per individual in our data set (Fig. 5C and Supplementary Figs. 3
and 4). We used an iterative variable selection procedure that
combines unsupervised stepwise forward and backward regres-
sion analyses [19] and identified main confounding variables,
including age, education level, sex and waist-to-hip ratios, that
contributed to higher risk of AD. We accounted for them in all
subsequent models (Fig. 5B).
We calculated the odds ratios (ORs) of each SNP and AD, which
quantifies the increase in likelihood of developing AD associated
with having a certain allele. We found that the major allele for the
PARP1 SNP rs3219134 (VAR01) confers a significantly higher risk of
AD (OR 1.42; 95% confidence interval (CI) 1.06–1.96, P value=
0.03; Fig. 5D, E and Supplementary Table 4). We then performed a
sensitivity analysis to generate a polygenic risk score for AD by
combining the risk genes identified in two meta-analyses
(Supplementary Figs. 3 and 4 and Supplementary Table 5)
[20, 21]. We validated that a higher polygenic risk score
corresponds to an increased risk of having AD in our cohort
(Supplementary Table 6). In the subset of participants with a
higher polygenic risk score for AD, we found that the major allele
for VAR01 is associated with higher risk of developing AD (OR 2.22;
95% CI 1.38–3.87, P value= 0.002; Fig. 5D, E). This indicates that
UK Biobank participants with the minor allele for VAR01 are 42%
less likely to have a positive AD diagnosis, and this association
increases to 222% in participants with a higher polygenic risk
score. We identified a different SNP in PARP1, rs78797064 (VAR02),
in the subset of patients with a lower genetic burden for AD
(Fig. 5D, E). The major allele of VAR02 is associated with a higher
risk of AD (OR 3.10; 95% CI 1.33–10.00, P value= 0.02; Fig. 5D, E).
Disturbed sleep, which occurs in 25–40% of patients with AD
[22, 23], impairs the quality of life of AD patients. It precedes other
markers like cognitive impairment and the severity of this
phenotype increases as the disease progresses [24]. Based on
our results which showed that PARP1 rescues excessive sleep
in flies, we investigated whether SNPs in PARP1 modulate sleep in
humans. First, we built a sleepiness score based on three criteria:
sleep duration, daytime sleepiness, and the absence of insomnia
(see “Curation of the UK Biobank data” in the “Methods” section
for further details). Using these scoring criteria, we calculated
β values, which quantifies the absolute change in the sleepiness
score given an exposure variable. We found that having a positive
AD diagnosis is the largest contributor of increased sleepiness























































































Fig. 2 Expression of toxic Aβ causes mitochondrial toxicity. A Ultrastructural analysis of adult brains in control (elavGal4>+) and Aβ-Arc-
expressing flies (elavGal4>Aβ-Arc) showing mitochondria with fragmented cristae in neuropiles (m, mitochondria). Represented TEM
micrographs of the indicated genotypes are shown. B Percentages of mitochondria in the neuropile that exhibit fragmented cristae (asterisks,
two-tailed chi-square test, 95% confidence interval). C Loss of Δψm in the brain mitochondria of flies expressing toxic Aβ-Arc. Representative
confocal images of whole mounted brains showing neurons loaded with TMRM are shown. The intensity levels of TMRM are visualised using a
five-tone heat map. D Expression of toxic Aβ-Arc causes a loss of Δψm in Drosophila neurons (mean ± SD; asterisks, two-tailed unpaired t test).
Y. Yu et al.
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Fig. 3 Diet interventions to improve nicotinate and nicotinamide metabolism reduce neurodegeneration in flies expressing toxic Aβ.
A The NAD+ levels of Aβ-expressing flies fed with the NAD+ precursor NAM are higher than those fed with normal food (mean ± SD; asterisks,
one-way ANOVA with Tukey’s multiple comparison test). Male flies were fed with food containing NAM post eclosion and sacrificed after day
15. B Pharmacological supplementation of NAM rescued Δψm in the brains of 5-day-old male flies (mean ± SD; asterisks, one-way ANOVA with
Dunnett’s multiple comparison test). C An illustration of the typical layout of the visible photoreceptors (red, R1–R7) at the surface of the adult
Drosophila ommatidia (grey hexagon). D Transmission electron micrograph showing individual ommatidia (yellow outlines) in the eye of
Aβ-Arc-expressing flies. Arrow points to an ommatidium where a photoreceptor neuron is missing. E Dietary supplementation with NAM
(5mM) rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks, two-tailed chi-square test, 95% confidence
interval). NF normal food. Genotypes: control, elavGal4>+; elav>Aβ-Arc, elavGal4>Aβ-Arc.
Y. Yu et al.
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Supplementary Table 7). Focussing our analysis on patients with
AD, we then found that the PARP1 SNP rs2230484 (VAR03)
modulates sleep in AD patients (β value −0.98; 95% CI −1.92 to
−0.05, P value= 0.04; Fig. 5G and Supplementary Table 8).
Combined, this data indicates that mutations in PARP in both
humans and flies affect sleep in AD. VAR03 is located in the exon 8
of the PARP1 gene (Fig. 5E) and leads to a missense mutation
(Pro377Ser) in the linker region after the DNA-binding domain
(Zn3) of PARP1. The structure of this region has not been
determined [25] so we did not pursue further analyses on VAR03.
VAR01 and VAR02 map to intron 17 and intron 14 of the PARP1
gene, respectively (Fig. 5E). We therefore asked whether they
could affect splicing of the PARP1 mRNA. To test this, we used
Human Splicing Finder [26] to investigate whether these two SNPs
have the potential of altering the splicing efficiency of PARP1. This
analysis indicates that VAR01 is a determinant of splicing
efficiency (Fig. 5H). This suggests that the minor allele of VAR01
might confer protective effects against AD by affecting the
splicing efficiency of PARP1.
Vitamin B is associated with a lower incidence and severity of
AD
Based on the observation of the protective effect of SNPs in
PARP1 from the UK Biobank participants, we investigated
whether the intake of vitamin B, which contains vitamin B3 or
NAM, is associated with a lower incidence and severity of AD. In
our full data set of 502,505 participants, 3940 participants
are described to take vitamin B and 1005 participants have AD.
We found that the vitamin B intake is associated with a 16%
decrease in the odds of having a positive diagnosis of AD in the
whole cohort (OR 0.86; 95% CI 0.37–1.67, P value= 0.67), while
accounting for education, age, sex, deprivation and obesity as
confounding variables (Fig. 6A and Supplementary Table 9). To
assess the robustness of this trend, we focussed our analysis on
the participants with a higher risk of developing AD as predicted
using our polygenic risk score. We found that the protective
effect of vitamin B is associated with a 455% decrease in the risk
of having AD (OR 0.22; 95% CI 0.01–0.99, P value= 0.14; Fig. 6B
and Supplementary Table 10).
To further investigate the protective effect of vitamin B, we
analysed whether vitamin B decreases sleepiness using our
sleepiness score, which we identified as a marker for AD. Vitamin
B deficiency causes excess sleepiness [27], and its supplementation
might improve vigilance [28]. We show that vitamin B intake is
associated with a 0.05 decrease in our sleepiness score (β value=
−0.05; 95% CI −0.10 to −0.005, P value= 0.03; Fig. 6C and
Supplementary Table 11). The protective effect of vitamin B against
sleepiness is two times stronger in the subset of patients with a
higher genetic risk of AD (β value −0.10; 95% CI −0.15 to −0.03,
P value= 0.005; Fig. 6D and Supplementary Table 12).
Taken together, our results show a protective trend for vitamin
B against AD as well as a decrease in a characteristic of AD,
sleepiness, in participants who take vitamin B.
The strengthening of these associations in the subset of
participants with a higher genetic risk reinforce the protective
trend for vitamin B.
Fig. 4 Mutation of Parp rescues mitochondrial toxicity associated with the expression of Aβ-Arc. A Flies overexpressing Aβ-Arc have higher
levels of poly ADP-ribosylation (mean ± SD; asterisks, two-tailed unpaired t test). B A Parpmutation increases NAD+ levels in Aβ-Arc-expressing
flies (mean ± SD; asterisks, one-way ANOVA with Dunnett’s multiple comparison test). C A Parp mutation rescues the loss of Δψm in the brains
of Aβ-Arc-expressing flies (means ± SD; asterisks, two-way ANOVA with Dunnett’s multiple comparison test). D A Parp mutation rescues the
total percentage of time spent asleep, as well as sleep during the light phase (asterisks, one-way ANOVA with Tukey’s multiple comparison test
for All phases and Light phase). E A Parp mutation rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks,
two-tailed chi-square test, 95% confidence interval). F A Parp mutation improves the lifespan of Aβ-Arc-expressing flies and significances were
determined using the log-rank, Mantel–Cox test. Genotypes: control, daGal4>+ (A), elavGal4>+ (B–F); da>Aβ-Arc, daGal4>Aβ-Arc (A), elav>Aβ
-Arc, elavGal4>Aβ-Arc (B–F).
Y. Yu et al.
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DISCUSSION
Deficiencies in NAD+ have been reported in age-associated
conditions, including cardiovascular, gastrointestinal and neurode-
generative diseases (reviewed in [16]). Here we report a decrease in
nicotinate and NAM metabolism and NAD+ levels in a fly model of
AD. NAD+ is synthesised via the de novo biosynthesis pathway and
recovered by recycling through the salvage pathway that recycles
NAM, the end product of NAD+ utilisation in cells. We showed that
dietary supplementation of NAM suppresses mitochondrial dysfunc-
tion and neurodegeneration. We also show that vitamin B, which
encompasses NAM, has protective effects against AD in humans.
Our results support a previous study showing a protective effect of
niacin, the amide derivative of NAM, against the development of AD
and cognitive decline [29]. The salvage pathway is particularly
attractive since boosting the availability of NAD+ precursors have
the potential to delay ageing and a wide range of diseases [30].
Based on the protective effect of NAM in a mouse model of AD, a
phase two clinical trial on using NAM as an early AD treatment has
been initiated (NCT03061474) in 48 participants.
We then showed that Parp mutation alleviates Aβ toxicity in flies
and replicated our results in humans by showing that variants in
PARP protects against AD using data from the UK Biobank. We used
Human Splicing Finder to investigate effect of these variants on
mRNA processing and found that the minor allele of a novel SNP,
Fig. 5 Gene variants in human PARP1 alter the risk and severity of AD. A Workflow of the analysis. Out of a total of 502,505 UK Biobank
participants, 432,747 patients who contained genomic data were analysed. B Descriptive statistics of the UK Biobank cohort that was analysed.
Either the number of participants in each category and their percentage with respect to the total cohort or the mean and standard deviation
are shown. A full table of summary characteristics is available in Supplementary Table 3. C Table of the 15 SNPs in PARP1 present in our cohort.
The SNP name (rsid), base position (bp), reference sequence (ref_seq), minor allele (minor) and minor allele frequencies are shown. This
information was extracted from the NCBI database. D Odds ratios of the significant SNP in PARP1 associated with the risk of AD and their
respective 95% confidence intervals. The odds ratios are calculated with respect to the allele shown in parentheses using individual binomial
models that accounts for covariates. Only the significant SNPs are shown. Statistics of all 15 SNPs analysed are shown in Supplementary Table
4. E Genomic location of the PARP1 SNPs that are significantly associated with AD risk (VAR01 and VAR02) as well as sleepiness in AD (VAR03,
explained in the next figure). F AD patients have a higher risk of sleepiness. β values with respect to the sleepiness score are calculated using a
linear regression, after accounting for age, sex, social deprivation (Townsend deprivation score), education and obesity. Only the significant
associations are shown. The numeric values of this model are in Supplementary Table 7. G β values of the model containing the significant
SNP (rs2230484) that is associated with differences in sleepiness in the subset of patients with AD. Statistics of all 15 SNPs investigated are
shown in Supplementary Table 8. H Theoretical impact of the SNP rs3219134 (T to C) on the gene-splicing efficiency. ESE Exonic Splicing
Enhancers, ESS Exonic Splicing Silencer, EIE exon-identity elements.
Y. Yu et al.
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VAR01 (rs3219134), may lead to differences in splicing efficiencies,
thus leading to a reduction in the total PARP1 protein levels.
However, these results are theoretical and require verification
experimentally. Our results confirm findings from a study showing
that the deletion of CD38, an NAD glycohydrolase, attenuates the
pathology of AD by increasing NAD+ levels [31]. These results
indicate that the suppression of the activity of NAD-consuming
enzymes could be a viable approach for neuroprotection in AD.
Future studies could probe the effect of genetic mutations in PARP1
and CD38 and the dietary intake of vitamin B on mitochondria in
patients. Novel positron emission tomography probes can be used
to quantify the function of mitochondrial complex 1 non-invasively
[32]. They may be used in combination with fluid biomarkers of
mitochondrial integrity [33, 34]. In addition, NAD+ can also be
obtained from other sources, such as bacteria present in the gut
microbiota. The presence of commensal bacteria that produce NAM
in the intestine of mouse model of amyotrophic lateral sclerosis
ameliorated their symptoms [35]. Future work could explore the
association between gut bacteria that produce NAM and neurode-
generative diseases.
In summary, we showed, using both genetic and pharmacological
approaches, that enhancing nicotinate and NAM metabolism
enhances mitochondrial function and results in neuroprotection in
a model of AD. Further, we provide evidence for a link between PARP
mutations and the severity of AD in humans using the UK Biobank.
METHODS
Genetics and Drosophila strains
Fly stocks and crosses were maintained on standard cornmeal agar media
at 25 °C. The strains used were elavGAL4 and daGal4 (Bloomington
Drosophila Stock Center # 458), w; UAS_Aβ42ARC; + (a kind gift from
D. Crowther, R&D Neuroscience, Innovative Medicines and Early Develop-
ment Biotech Unit, AstraZeneca, Cambridge, UK) and w; +; parpCH1 (a kind
gift from V. Corces, Department of Biology, Emory University, Atlanta, USA).
Metabolic profiling
Global metabolic profiles were obtained using the Metabolon Platform
(Metabolon Inc., NC, USA) as previously described [15]. Whole female flies
aged 15 days after eclosion were used. Toxic Aβ42Arc was expressed using
the ubiquitous daughterless (da) Gal4 driver in the whole fly. Each biological
replicate comprises 100 15-day-old adult female flies (approximately 100mg
per replicate), with a total of 7–8 replicates per genotype. For sample
extraction, a 80% (v/v) methanol:water solution was used. Samples were then
prepared for liquid chromatography–mass spectrometry. Compounds above
the detection threshold were identified by comparison with library entries of
purified standards or recurrent unknown entities. Subsequent analyses were
performed using MetaboAnalystR [36]. Undetected metabolites are imputed
with the minimum. Identification of known chemical entities was based on
comparison with metabolomic library entries of purified standards. Each
biochemical is rescaled to set the median equal to 1. Values for each sample
are normalised by Bradford protein concentration. The processed values of
each metabolite are shown in Supplementary Table 1.
Drug treatments
NAM was incorporated directly into the fly food at a final concentration of
5 mM. Crosses were set up on normal food and transferred to NAM-
containing food after 2 days. Larvae were treated with NAM throughout
development. The adult flies were kept on drug-containing food
throughout their lifespan, and they were transferred to vials with fresh
food every 2–3 days. Flies from each genotype were randomly assigned to
normal food and food supplemented with NAM.
Quantitation of NAD+ and PAR levels
NAD+ concentrations were measured using the NAD+/NADH EnzyChrom
colorimetric assay according to the manufacturer’s instructions (BioAssay

























Target variable Confounder variable
***
Whole cohort Subset with high genetic risk for AD
Whole cohort Subset with high genetic risk for AD
Fig. 6 Vitamin B alters the risk and severity of AD. A There is a trend for vitamin B being protective against AD in the whole UK Biobank cohort
(OR 0.86; 95% CI 0.37 to 1.67, P value= 0.67). See Supplementary Table 9 for details. B This trend is more robust in participants with a higher
genetic risk for AD (OR 0.22; 95% CI 0.01 to 0.99, P value= 0.14). See Supplementary Table 9 for details. C Vitamin B intake is associated with
decreased sleepiness in the whole cohort (β value=−0.05; 95% CI −0.10 to −0.005, P value= 0.03, see Supplementary Table 11 for details) and
D individuals with high genetic risk for AD (β value=−0.10; 95% CI −0.15 to −0.03, P value= 0.005, see Supplementary Table 12 for details).
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Systems, CA, USA) as previously described [15]. Briefly, two whole male flies
were homogenised in the specified buffer on ice at time ZT-06. NAD+
concentrations were normalised to total protein, measured using the
bicinchoninic acid assay. The normalised NAD+ levels are divided by the
average of controls, which were elav>+. Three biological replicates or
more were performed for each condition.
PAR levels in flies were determined using the PAR ELISA Kit (Cell Biolabs,
XDN-5114). Briefly, 30 whole male flies aged 20 days were used per
biological replicate. Samples were frozen using liquid nitrogen and
homogenised in radioimmunoprecipitation assay buffer on ice (Thermo
Scientific, CAT-89900) containing PARP inhibitors at time ZT-06. The
following steps of the assay were performed according to manufacturer’s
standard instructions. Absorbance was measured at 450 nm. Assays were
conducted on 96-well microtiter plates using an Infinite M200Pro
multifunction reader (TECAN, Mannedorf, Switzerland).
Locomotor assays and lifespan analysis
Adult male flies were aged to 10 days old post eclosion and individually
loaded in glass tubes (80mm× 5mm× 3mm) containing the same food
used for rearing. The flies were grown and analysed in a light/dark 12 h/
12 h cycle at 25 °C. The total number of recorded midline crossings per
minute was recorded using the Drosophila Activity Monitoring System
(Trikinetics, Waltham, MA), and the data were analysed using Rethomics
[37]. The analysis started at the first ZT0 to allow acclimation. Sleep was
calculated for the first 5 days and the data of flies that died were discarded.
Sleep is defined as 5min of inactivity. One-way analysis of variance with
Tukey’s multiple comparison test was used to determine significance for
the fraction of time asleep. The data for lifespan analysis are presented as
Kaplan–Meier survival distributions. We recorded the entire lifespan of the
flies from 10 days post-eclosion until their death and determined statistical
significance using the log-rank test. We provide the full analysis script and
the raw data in our GitHub repository: https://github.com/M1gus/AD_Parp.
Pseudopupil analysis
The heads of 4–5-day-old flies were directly fixed on standard
microscope slides using quick-dry transparent nail varnish as described
[38]. A Zeiss Axioplan 2 microscope equipped with a ×63 oil immersion
objective was used to visualise the ommatidia. In all, 5–8 flies per
condition were examined, to obtain a total number of around 200
ommatidia or ~1400 rhabdomeres. The percent abnormal rhabdomeres
was calculated as the number of degenerate rhabdomeres over the
total number of rhabdomeres: (A × 1+ B × 2+ C × 3)/N, where A=
number of ommatidia with 6 rhabdomeres, B= number of ommatidia
with 5 rhabdomeres, C= number of ommatidia with 4 rhabdomeres and
N= total number of ommatidia counted. Statistical significance was
determined using chi-squared test.
Microscopy-based assessment of mitochondrial function and
morphology
Measurements of Δψm in fly brains were performed as previously
described [39]. Briefly, fly brains were loaded for 40min at room
temperature with 40 nM TMRM in loading buffer (10mM HEPES pH 7.35,
156mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25mM KH2PO4, 2 mM CaCl2,
10mM glucose) and the dye was present during the experiment. In these
experiments, TMRM is used in the redistribution mode to assess Δψm, and
therefore a reduction in TMRM fluorescence represents mitochondrial
depolarisation. Confocal images were obtained using a Zeiss LSM 880
confocal microscope equipped with a ×40 oil immersion objective.
Illumination intensity was kept to a minimum (at 0.1–0.2% of laser output)
to avoid phototoxicity and the pinhole was set to give an optical slice of
2 μm. Fluorescence was quantified by exciting TMRM using the 565 nm
laser and measured above 580 nm. Z-stacks of 5 fields of 300 μm2 each per
brain were acquired, and the mean maximal fluorescence intensity was
measured for each group.
Electron microscopy
For TEM, adult fly thoraces were fixed overnight in 0.1 M sodium
cacodylate buffer (pH 7.4) containing 2% paraformaldehyde, 2.5%
glutaraldehyde and 0.1% Tween-20. Samples were post-fixed for 1 h at
room temperature in a solution containing 1% osmium tetroxide and 1%
potassium ferrocyanide. After fixation, samples were stained en bloc with
5% aqueous uranyl acetate overnight at room temperature; the samples
were then dehydrated via a series of ethanol washes and embedded in
TAAB epoxy resin (TAAB Laboratories Equipment Ltd., Aldermaston, UK).
Semi-thin sections were stained with toluidine blue, and areas of the
sections were selected for ultramicrotomy. Ultrathin sections were
stained with lead citrate and imaged using a MegaView 3 digital camera
and iTEM software (Olympus Soft Imaging Solutions GmbH, Münster,
Germany) in a Jeol 100-CXII electron microscope (Jeol UK Ltd., Welwyn
Garden City, UK).
Statistical analyses
Statistical analyses were performed using GraphPad Prism 9 (www.
graphpad.com). The data are presented as the mean values, and the error
bars indicate ±SD. The number of biological replicates per experimental
variable (n) is indicated in either the respective figure or figure legend. No
sample was excluded from analysis, unless otherwise stated. Blinding was
not done. Significance is indicated as an asterisk (*) for P < 0.05, double
asterisks (**) for P < 0.01, triple asterisks (***) for P < 0.001, four asterisks
(****) for P < 0.0001 and NS for P ≥ 0.05. We compiled all biochemical data
into a Prism file and uploaded this in our GitHub repository: https://github.
com/M1gus/AD_Parp.
Digital image processing
Fluorescence and TEM images were acquired as uncompressed bitmapped
digital data (TIFF format) and processed using Adobe Photoshop,
employing established scientific imaging workflows [40].
UK Biobank data sources
The UK Biobank comprises health data from over 500,000 community
volunteers based in England, Scotland and Wales. Information about the
geographical regions, recruitment and other characteristics has been
previously described [18]. Informed consent was obtained from all
subjects. Briefly, between 2006 and 2010, adults aged between 40 and
69 years within close proximity to 1 of the 22 UK Biobank recruitment
centres were invited to participate. Individuals had extensive demographic,
lifestyle, clinical and radiological information collected. Baseline assess-
ments also included a comprehensive series of questionnaires, face-to-face
interviews, physical examinations and blood sampling, with linkages to
electronic medical records.
Clinical data on neurodegenerative disorders and other comorbidities
were cross-validated by an algorithm from the UK Biobank, which took into
consideration the UK Biobank baseline assessment data (verbal interview),
linked hospital admissions data and death register data. Specifically, the
diagnosis of neurodegenerative diseases and dementia relied on
consensus between primary care and hospital admissions and/or mortality
data. This method has been previously validated using a subset of the UK
Biobank participants and was shown to have high accuracies of detecting
true positives [41]. The full protocol is publicly available, and summary data
can be viewed on the UK Biobank website (www.ukbiobank.ac.uk).
Vitamin B is a group of eight nutrients. Information on the intake of
medications and supplements is obtained through verbal interviews via a
touch screen-based questionnaire as detailed in the manual that details the
interview procedure at an Assessment Centre of the UK Biobank [42]. To
record the use of a medication, the UK Biobank interviewer selects the
medication from a comprehensive list of all medications available in Britain.
The variable we used for vitamin B intake is labelled as “vitamin b compound
tablet”. We then grouped NAM and niacin, which are components of vitamin
B, into the vitamin B variable. Dose information was not collected. We
excluded specific forms of vitamin B that were unrelated to vitamin B3:
vitamin B1, vitamin B6, cantassium vitamin b6, and vitamin b12.
UK Biobank ethical approval was granted from the North West Multi-
Centre Research Ethics Committee. The current analysis was approved
under the UK Biobank application #60124. A detailed list of the variables of
the present study is presented in Supplementary Table 2 and their
distributions are shown in Supplementary Figs. 1–4.
Curation of the UK Biobank data
For the analysis of the relationship between mutations in PARP1 and AD,
we first selected UK Biobank participants whose genome was sequenced.
We did not perform any imputation on the genomic data. We then created
a sleepiness score by adding sleep duration (in hour) and daytime
sleepiness (self-reported score of range 0 to 3) and the absence of
sleeplessness or insomnia (self-reported score of range 0 to 2). Details of
these variables can be found on the UK Biobank website (https://biobank.
ndph.ox.ac.uk/showcase/label.cgi?id=100057).
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We used an exploratory approach to select the main comorbidities that
influence the risk of AD. The putative comorbidities are presented in
Supplementary Table 3. We applied an iterative variable selection
procedure combining unsupervised stepwise forward and stepwise
backward regression analyses to select the most suitable predictor or
combination of predictors in our models based on the Akaike information
criterion. These were age, waist-to-hip ratio, sex, ethnicity, education level,
social deprivation (Townsend deprivation index) and sleepiness.
We then built a polygenic risk score as a predictor of the genetic burden
for AD. We fitted binomial regression models where the response variables
were whether a participant had a positive diagnosis for AD against SNPs
identified previously [20, 21]. We then created the polygenic risk score by
multiplying the OR value of each SNP against the number of the allele
present. We validated this score and found that it significantly increases
the risk of AD in our cohort (Supplementary Tables 5 and 6).
Analysis of the UK Biobank data
To determine whether any SNP in PARP1 identified in our cohort influence
the risk of AD, we built individual binomial models iteratively for each
PARP1 SNP, where the response variable was AD and accounting for the
covariates identified in the “UK Biobank data curation” section to account
for potential linkage effects. We repeated this process for people with a
higher and lower genetic burden as determined by our polygenic risk
score. Finally, this same workflow was applied to identify any modulators
of sleepiness by changing the response variable to our sleepiness score
and the type of model to linear regressions.
For each model, we calculated the OR or risk ratio and their 95% CIs to
quantify the effects of the independent variables on the response
variables. The models were built using the MASS package [19] in R. The
comparison tables were generated using the Stargazer package [43]. The
analysis source code, detailed quality checks and all supplementary
material are available in GitHub (https://github.com/M1gus/AD_Parp).
CODE AVAILABILITY
Code generated in this manuscript is deposited in GitHub (https://github.com/
M1gus/AD_Parp).
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